Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Another reason to move to the NASDAQ..
Not having to write everything in French. Pointless waste of energy. The French are probably not even interested . They probably don't even know what the NHS is or it's significance . We do bugger all business in France, why are we bothering....
I will say one more thing on this. The fact that the market currently is only willing to pay half of fair value in my opinion means that worst case scenario is already baked into the stock price. With the possibility of a large contract landing on our doorstep any day, who would want to be out of this stock at these prices?
Yeah and that's why you're invested here and not there, me too! If the market acts a certain way make it work for you, don't moan that it's not being rational! That's what we are doing by getting in here early...
God only knows where we'll end up with these discussions.
The discussion appears to move almost seamlessly from Divorced From Reality to Keeping the Faith.
If it carries on like this, we'll need the Samaritans !!
IMO, that is showing a total lack of confidence after a great innovative RNS and just playing into MM'S hands, whoever and wherever they are.
@HarChris
I was already an investor in the good old days of the dot com bubble. I know what can happen to tech companies of which investors assume their growth path will never end.
But Jungla, if a company turns over 5 million one year, then 10 million, then 20 million, then 40 million, you can start to predict what the likely revenues will be in the future, right? How does that compare to a company that goes from £11.5m to £277m thanks to a pandemic which ncyt took full advantage of? It's light and day!
Again I agree with you and that's why I'm invested. The market isn't used to this sort of situation though and is waiting til the future becomes clearer before accurately valuing it.
@HarChris
You are right and you are wrong.
It is indeed impossible to predict what sort of revenue ncyt will be making in 2023 (although we can get a very good idea already). However is equally impossible to predict what revenue a "growth" company will be making in 3, 5 or especially 10 years time. And yet analysts calculate fair value based on estimates of the next 5 years, in the States even the next 10 years! Who can predict what will happen in 10 years time? And yet, for those same growth companies investors are prepared to pay up to 2, 3, 4 or even 5 times fair value. For Nova they are currently prepared to pay half (!) of fair value. This is absolutely ridiculous. In my opinion, both cases are equally hard to predict, but I know one thing: the Nova share price presents infinitely more value than those supposedly eternally growing growth companies. For this reason I consider Nova an absolute no brainer.
Love it Wilson.
Should be in the footer of your posts.
There is one thing the market makers are forgetting and that is some of us are extremely stubborn.
Held.....Holding......Gold.
It was a mistake and then I thought that's cool lol.
I don't buy it Bramley, p/e ratios are useless at this stage. Growth companies see 20, 30 40 percent growth in revenue/profits a year, we aren't likely to see that (if we do the share price will go parabolic). We're also not a blue chip that commands a p/e of ~15. So what p/e should we have currently?
What sort of revenue ncyt will be making in 2023 is absolutely impossible to say right now. What we can say is this is a golden opportunity to take a micro cap stock and transform it into a midcap, no doubt about that. So what do we do? We invest now and we wait and when the company proves itself over an eighteen month, maybe two year period and the future becomes ever clearer, true value will be realised. And we'll be handsomely rewarded.
Not to mention they are expanding stateside and it would probably add to their credibility and further support stateside orders.
Hi porky is on the right lines
If we moved then the company’s P/E ratio would be more likely to be bought online with its peers. I only put that in my comments as imho I feel that would be a logical step in being a global player. Time will tell
Regards
Bramley 1967
The sooner at takeover bid is made the better HarChris. If it's a cr*p offer then it will get regected but the offer alone would attract more P.R.and subsequent S.P. rise than any recent RNS has.
The only benefit would be to make this less of a T/O target but if a hostile takeover attempt is made at say £9 a share, it would be worth investors rejecting en masse and we'll see the share price get a boost from that alone...
Can you explain what benefit to the company moving to the Nasdaq would have? I thought this sort of move was useful for companies seeking extra investment, not companies drowning in cash? I suppose in years to come when the business is in a completely different position it might be useful but you don't relist simply to give the sp a little boost.
@Bramley1967
Totally agree on all parts
I totally agree and really think a move to the NASDAQ would be the way forward now:-
* 1 set of regulations / 1 language
* A market that understands diagnostics
* A significantly bigger market and significantly greater reach
* Correctly rated on a PE ratio in line with our peers
* Quarter updates
As it stands we are simply NOT getting any recognition on the aim. Investors here want to chase Rainbows and buy stocks on Hype not substance. If they issue a trade update they get complaints, if they issue an R&D update they get complaints, they cant win frankly yet the business is still delivering great results.
They are making more profits than ASOS yet shareholders are piling into "potential stocks" with higher market caps that haven't delivered a bean on profit yet. Its total madness.
So if this is it, this is how its going to be then a move to the NASDAQ is the only answer because at the current diabolically low MCAP its now a sitting duck for an acquisition - maybe that's what's going on behind the scenes ????? because II are still adding and the SP is drifting.
Bramley,
Calmly reassuring post - thank you!
Good afternoon all.
Well after my post last night telling you all to keep faith in the company and the management team they clearly delivered this morning. It certainly shows me that the company hasn’t taken its foot of the pedal it fact it’s changed up a gear. I think we are among the very few who can say that the company continues to keep its first to market competitive advantage in our field. Not only that we are looking beyond Covid. We must remember that this was an R&D update and wasn’t there to confirm earnings etc. Where we differ from so many others Is we only give facts on the products there isn’t any ifs or maybes. I think we have already read between the lines that we are bringing to market tests that are being asked for and that will be and are being used in our own nhs. This seems to be confirmed by the French RnS about promate.
Although we haven’t had a massive rise on sp today this seems to have started to reverse the trajectory we were on. From past experience the R&D updates need time for investors and the market to digest before we see a big movement.
It certainly seems that our next step will start to release details of contracts done. Looking at the rns this gives me great hope that this could be anywhere globally as we have tests that are needed globally. It wouldn’t surprise me in the next couple of months for us to be listed on the USA stock exchange as I see this as a natural progression if we are getting more involved over the pond. Time will tell on that one.
For now though let’s breathe a sigh of relief for what was some very positive news.
Imho still a billion pound mcap in the making Sp1500
Regards
Bramley 1967 ??